EFNA5 and benign prostatic hyperplasia: To further investigate the clinical application value of serum ephrin-A5 as a PCa marker, we assessed the content of serum ephrin-A5 in 55 patients with PCa and 40 patients with BPH and found that the serum concentration of ephrin-A5 in the PCa group was not significantly different from that in the BPH group (Fig. 7A).